Option Care Health (OPCH) Stock News

William Blair cut its rating on Option Care Health to Market Perform from Outperform.

Moody's placed Option Care Health's ratings on review for downgrade following the company's announcement of a leveraged buyout. The review will assess the impact of increased leverage on the credit profile.

JP Morgan cut its recommendation on Option Care Health to Neutral, previously Overweight.

Citizens JMP downgraded Option Care Health (OPCH) to Market Perform from Market Outperform. No price target was provided.

Jefferies raised its price target on Option Care Health (OPCH) to $32.05 from $28.00. No rating change was disclosed.

Barrington Research cut its rating on the home-infusion provider to Market Perform from Outperform, removing the buy-equivalent rating.

CD&R and McKesson will acquire Option Care Health for $32.05 per share, valuing the at-home infusion therapy provider at about $5.8 billion. The deal is expected to close in the first half of 2027.

OPCH shares resumed trading after a halt for pending news. No reason has been disclosed.

Option Care Health (OPCH) halted after announcing a definitive agreement to be acquired by CD&R and McKesson for $32.05/share, a 37% premium. CD&R takes majority control; McKesson invests $1.4B for 49%. Deal expected to close H1 2027.

CD&R to hold about 51% majority stake in Option Care Health.

Option Care Health will remain a separate company led by its own management team. The news follows a trading halt and guidance withdrawal earlier today.